Genflow Biosciences

Pursuing scientifically sound approach to developing gene therapies that slow or reverse ageing in Dogs and Humans

[Genflow Biosciences @GenflowBioIR]

We’ve launched new social media profiles on LinkedIn and Twitter (our YouTube channel is under construction). Stay up to date on all the exciting news happening at GenFlow Biosciences by taking a moment to visit our new pages:

LinkedIn: @GenflowBiosciences
Twitter: @GenflowBioIR

[Genflow Biosciences @GenflowBioIR]

📣 A reminder to shareholders that Genflow Biosciences’ Annual General Meeting will be held today, 29 June 2026, at 11:00 a.m. at One Heddon Street, London, W1B 4BT.

We look forward to welcoming shareholders attending in person. 🧬

[Genflow Biosciences @GenflowBioIR]

📣 Genflow Biosciences will be at BIO International Convention 2026 in San Diego this week!

Chairman Gad Berdugo will also join a panel discussion on the future of RNA therapeutics and where the field could see the greatest advances. 🧬

$GENF

[Genflow Biosciences @GenflowBioIR]

📣 Genflow will present results from its SLAB study at the Animal Longevity Summit 2026.

The data will highlight progress from Genflow's veterinary longevity programme and its SIRT6 gene therapy approach.

For the full release, see Genflow's profile on the London Stock Exchange.

[Genflow Biosciences @GenflowBioIR]

Mark your calendars!

Genflow Biosciences has announced its Annual General Meeting.

📍 One Heddon Street, London, W1B 4BD
📆 Monday 29 June 2026
🕚 11:00 A.M.

Read the release: https://t.co/eNrh2mRkBc

[Genflow Biosciences @GenflowBioIR]

🧬 Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has a busy calendar!

From upcoming conferences and anticipated patent developments to final SLAB trial data, several important milestones remain on the horizon as #GENF advances its #SIRT6 therapies.

[Genflow Biosciences @GenflowBioIR]

🧬 Genflow Biosciences (LON:GENF) (OTCQB:GENFF)’ canine longevity study continues to demonstrate encouraging progress!

With 100% survival across treated dogs through seven months and ongoing evaluation, the study continues to support the potential of #SIRT6-based therapies.

[Genflow Biosciences @GenflowBioIR]

Want to learn more about Genflow?

Sign up for our newsletter to stay in the loop: https://t.co/VabvLPxoY2

#GENF #GENFF #biotech #longevity

[Genflow Biosciences @GenflowBioIR]

Missed our FY 2025 Results?

Find the full release, financial highlights, and operational updates from Genflow Biosciences here: https://t.co/6JQ25IVawY

#GENF #GENFF

[Genflow Biosciences @GenflowBioIR]

Genflow Biosciences' 2025 Final Results are available now!

The Annual Report is now available, offering a detailed look at the Company’s progress across its longevity-focused pipeline and strategic priorities.

Read the release: https://t.co/8EkgHZAZ8J

[Genflow Biosciences @GenflowBioIR]

🧬 Genflow Biosciences | Program Update: GF-1002 (MASH)

🎯 Focus on advanced fibrosis
🔬 New HCC prevention data
📄 IND in progress
⚙️ Exploring mRNA/LNP delivery

Targeting a segment with limited treatment options.

[Genflow Biosciences @GenflowBioIR]

🧬 Genflow Biosciences expands engagement with Tier-1 animal health players via new confidentiality agreements.

More industry leaders are now reviewing its canine SIRT6 programme following positive early data - further validation as discussions continue.https://t.co/SSyTCcQ5Vu

[Genflow Biosciences @GenflowBioIR]

Missed last week's release?

🧬 Genflow partners with Acuitas Therapeutics:
✅ Non-dilutive and fully funded
✅ Utilizes advanced LNP delivery technology
✅ Progressing the SIRT6 mRNA program

Find out more here: https://t.co/6JQ25IVawY

[Genflow Biosciences @GenflowBioIR]

🧬 $GENF CEO Dr Eric Leire outlines key progress & what’s ahead in a new @DirectorsTalk interview.

Highlights include:
🧬 Large market opportunity across MASH, sarcopenia, and glaucoma
🧬 Potential non-dilutive revenue through animal health licensing

🔗 https://t.co/HlMX1ZF0zm

[Genflow Biosciences @GenflowBioIR]

🧬 Genflow Biosciences (LSE: GENF | OTCQB: GENFF) enters a strategic collaboration with Acuitas Therapeutics:

✔️ Fully funded, non-dilutive
✔️ Access to leading LNP tech
✔️ Advancing SIRT6 mRNA programme

A clear step forward in platform validation and development.

#GENF

[Genflow Biosciences @GenflowBioIR]

Missed last week's update on the #SLAB trial?

#Genflow's 3-month follow-up showed:

#GENF #GENFF #Aging #SIRT6

[Genflow Biosciences @GenflowBioIR]

🧬 @GenflowBioIR is investigating the potential of #SIRT6-driven gene therapy in glaucoma, a leading cause of irreversible #blindness.

By addressing underlying #aging processes and #DNA repair mechanisms, the goal is to shift beyond management toward vision preservation.

[Genflow Biosciences @GenflowBioIR]

🧬 Genflow reports continued positive data from its SLAB trial.

3-month follow-up shows sustained improvements, no adverse events, and strong safety profile for its SIRT6 gene therapy in aged dogs.

Study ongoing → more data expected.

#GENF #GENFF #biotech

[Genflow Biosciences @GenflowBioIR]

Strong leadership is key to turning scientific progress into real world impact.

#Genflow’s team brings together deep expertise across biotech, clinical development, and capital markets - guiding the Company’s mission.

Meet the team: https://t.co/SKDa0NQiHC

#GENF #GENFF

[Genflow Biosciences @GenflowBioIR]

A recent survey suggests many Americans would rather live a shorter, healthier life than a longer one burdened by diseases that diminish #QoL.

@GenflowBioIR is advancing innovations in aging with the goal of supporting both longevity & healthspan.

🔗 https://t.co/Z7whFP9Qkm

[Genflow Biosciences @GenflowBioIR]

Haven't had a chance to read @GenflowBioIR CEO Dr. Eric Leire's interview with Pharma Source?

Catch up here: https://t.co/J3YisUCWZi